AU2013333928B2 - Novel recombinant Bordetella strains - Google Patents

Novel recombinant Bordetella strains Download PDF

Info

Publication number
AU2013333928B2
AU2013333928B2 AU2013333928A AU2013333928A AU2013333928B2 AU 2013333928 B2 AU2013333928 B2 AU 2013333928B2 AU 2013333928 A AU2013333928 A AU 2013333928A AU 2013333928 A AU2013333928 A AU 2013333928A AU 2013333928 B2 AU2013333928 B2 AU 2013333928B2
Authority
AU
Australia
Prior art keywords
gene
protein
strain
fha
bordetella pertussis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013333928A
Other languages
English (en)
Other versions
AU2013333928A1 (en
Inventor
Hana KAMMOUN
Camille Locht
Nathalie Mielcarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur, Universite de Lille filed Critical Institut Pasteur de Lille
Publication of AU2013333928A1 publication Critical patent/AU2013333928A1/en
Application granted granted Critical
Publication of AU2013333928B2 publication Critical patent/AU2013333928B2/en
Assigned to INSTITUT PASTEUR DE LILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LILLE reassignment INSTITUT PASTEUR DE LILLE Request for Assignment Assignors: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE LILLE, UNIVERSITE DROIT ET SANTE LILLE II
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2013333928A 2012-10-17 2013-10-17 Novel recombinant Bordetella strains Active AU2013333928B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306279.6A EP2722338A1 (en) 2012-10-17 2012-10-17 Novel recombinant Bordetella strains
EP12306279.6 2012-10-17
PCT/EP2013/071724 WO2014060514A1 (en) 2012-10-17 2013-10-17 Novel recombinant bordetella strains

Publications (2)

Publication Number Publication Date
AU2013333928A1 AU2013333928A1 (en) 2015-04-09
AU2013333928B2 true AU2013333928B2 (en) 2017-11-30

Family

ID=47073385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013333928A Active AU2013333928B2 (en) 2012-10-17 2013-10-17 Novel recombinant Bordetella strains

Country Status (10)

Country Link
US (1) US9528086B2 (OSRAM)
EP (3) EP2722338A1 (OSRAM)
JP (3) JP6473086B2 (OSRAM)
CN (2) CN104936976B (OSRAM)
AU (1) AU2013333928B2 (OSRAM)
CA (1) CA2887055C (OSRAM)
DK (2) DK2909229T3 (OSRAM)
ES (2) ES2715651T3 (OSRAM)
SG (2) SG10201706392YA (OSRAM)
WO (1) WO2014060514A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800244A1 (en) 2006-03-10 2021-04-07 Institut Pasteur de Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
WO2010125014A1 (en) 2009-04-28 2010-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
CA2854110C (en) 2011-11-02 2019-06-25 Institut Pasteur De Lille Effect of an attenuated bordetella strain against allergic disease
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
KR101672719B1 (ko) * 2014-07-22 2016-11-04 전남대학교산학협력단 바이러스 중화항원 단백질 발현을 위한 보르데텔라 백일해 균주 및 이를 이용한 면역원성 조성물
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
CN108025053A (zh) 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
CN109069535B (zh) 2016-03-29 2022-03-18 里尔巴斯德研究所 突变型博德特氏菌属菌株及其使用方法
CA3077428A1 (en) 2017-10-18 2019-04-25 Institut Pasteur De Lille Bordetella strains expressing serotype 3 fimbriae
EP3906049A1 (en) * 2019-01-04 2021-11-10 Boehringer Ingelheim Animal Health USA Inc. Attenuated bordetella bronchiseptica strains, oral vaccines containing the attenuated strains, and methods of making & use thereof
JP2023540453A (ja) 2020-08-14 2023-09-25 イリアド バイオテクノロジーズ，リミテッド ライアビリティ カンパニー 凍結乾燥生ボルデテラワクチン
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases
CA3195783A1 (en) * 2020-11-17 2022-05-27 Keith Rubin Treatment and prevention of neuropathology associated with neurodegenerative diseases
CN113429188B (zh) * 2021-06-18 2022-06-10 湖北沛高环保科技有限公司 一种尾矿固废综合处理利用方法
CN116265584A (zh) * 2021-12-17 2023-06-20 远大赛威信生命科学(南京)有限公司 百日咳抗原重组表达载体及其工程菌和应用
WO2025257397A1 (en) * 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
CN118853525B (zh) * 2024-09-26 2025-01-07 上海羽冠生物技术有限公司 经修饰的百日咳鲍特菌菌株

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
WO2004091519A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
EP3800244A1 (en) * 2006-03-10 2021-04-07 Institut Pasteur de Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
WO2008058396A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
AU2008266910A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
JP2011116659A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 組換え皮膚壊死トキソイドを含有する豚萎縮性鼻炎用薬剤
WO2010125014A1 (en) 2009-04-28 2010-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
CN102802665B (zh) 2009-06-15 2015-11-25 新加坡国立大学 流感疫苗、组合物及使用方法
CA2854110C (en) 2011-11-02 2019-06-25 Institut Pasteur De Lille Effect of an attenuated bordetella strain against allergic disease
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RUI LI ET AL, "Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route", BIOENGINEERED BUGS, 2011, vol. 2, no. 6, pages 315 - 319. *
RUI LI ET AL, "Development of live attenuated strains expressing the universal influenza vaccine candidate M2e", VACCINE, 2011, vol. 29, no. 33, pages 5502 - 5511. *

Also Published As

Publication number Publication date
JP2021164481A (ja) 2021-10-14
AU2013333928A1 (en) 2015-04-09
JP6473086B2 (ja) 2019-02-20
CN110923181A (zh) 2020-03-27
HK1213926A1 (en) 2016-07-15
JP2019088303A (ja) 2019-06-13
US9528086B2 (en) 2016-12-27
EP2909229A1 (en) 2015-08-26
SG10201706392YA (en) 2017-09-28
EP2909229B1 (en) 2018-12-12
SG11201502010TA (en) 2015-04-29
WO2014060514A1 (en) 2014-04-24
DK2909229T3 (en) 2019-03-25
EP3459966A1 (en) 2019-03-27
ES2771675T3 (es) 2020-07-06
CN104936976A (zh) 2015-09-23
US20150210978A1 (en) 2015-07-30
CA2887055C (en) 2023-03-21
DK3459966T3 (da) 2020-02-17
JP2015536134A (ja) 2015-12-21
CA2887055A1 (en) 2014-04-24
CN104936976B (zh) 2019-11-22
EP2722338A1 (en) 2014-04-23
JP7277516B2 (ja) 2023-05-19
JP6914976B2 (ja) 2021-08-04
ES2715651T3 (es) 2019-06-05
EP3459966B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
JP7277516B2 (ja) 組換えボルデテラ株
DK1994139T3 (en) Live, attenuated Bordetella strain as a single dose vaccine against whooping cough.
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
Marzouqi et al. Development of improved vaccines against whooping cough: current status
JP2023503058A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
Olivera et al. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection
Ho et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates
Li et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e
Reveneau et al. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis
JP6401148B2 (ja) 抗原および抗原の組み合わせ
HK40003310A (en) Novel recombinant bordetella strains
HK40003310B (en) Novel recombinant bordetella strains
HK1213926B (en) Novel recombinant bordetella strains
US20150238590A1 (en) Use of the salmonella spp type iii secretion proteins as a protective vaccination
Ghorbani et al. Recombinant flagellin protein can efficiently protect mice against Salmonella typhi
CN107080840A (zh) 轮状病毒‑霍乱联合疫苗及其制备方法
CN101400783B9 (zh) 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗
HK40048647A (en) Live attenuated bordetella strains as a single dose vaccine against whooping cough
Guzmàn et al. Use of Salmonella Spp. Carrier Strains to Deliver Bordetella Pertussis Antigens in Mice using the oral Route
Olivera et al. Research Article Immunization with the Recombinant Cholera Toxin B Fused to Fimbria 2 Protein Protects against Bordetella pertussis Infection
Locht et al. Bordetella pertussis Highly Attenuated
Locht et al. Pertussis Toxin Improves Immune

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INSTITUT PASTEUR DE LILLE

Free format text: FORMER OWNER(S): INSTITUT PASTEUR DE LILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DROIT ET SANTE LILLE II

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

Free format text: FORMER OWNER(S): INSTITUT PASTEUR DE LILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DROIT ET SANTE LILLE II

Owner name: UNIVERSITE DE LILLE

Free format text: FORMER OWNER(S): INSTITUT PASTEUR DE LILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DROIT ET SANTE LILLE II